
Quarterly report 2022-Q2
added 08-18-2022
CureVac N.V. Net Debt 2011-2026 | CVAC
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt CureVac N.V.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -783 M | -1.27 B | 35.8 M | -21.4 M | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 35.8 M | -1.27 B | -509 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.79 | -1.15 % | $ 4.31 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
AbCellera Biologics
ABCL
|
14.7 M | $ 3.49 | 0.58 % | $ 1.04 B | ||
|
Frequency Therapeutics
FREQ
|
21.7 M | - | - | $ 528 M | ||
|
argenx SE
ARGX
|
-89.9 M | $ 700.45 | -1.19 % | $ 25 B | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.6 | 1.41 % | $ 8.66 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Grifols, S.A.
GRFS
|
5.36 B | $ 7.81 | -2.01 % | $ 6.83 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 225.98 | -1.32 % | $ 5 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
ADC Therapeutics SA
ADCT
|
-459 M | $ 4.13 | -5.06 % | $ 105 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | ||
|
BioCardia
BCDA
|
212 K | $ 1.26 | -0.79 % | $ 26.7 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Anika Therapeutics
ANIK
|
-46 M | $ 14.2 | -0.7 % | $ 208 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
Athersys
ATHX
|
-27.6 M | - | 3.77 % | $ 22.4 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 91.19 | 1.21 % | $ 27.2 B | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
-187 M | $ 1.44 | -1.37 % | $ 367 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-206 M | $ 6.68 | -4.57 % | $ 183 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
AVEO Pharmaceuticals
AVEO
|
-48 M | - | - | $ 521 M | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 7.92 | 1.67 % | $ 1.31 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.54 | -5.22 % | $ 16 M | ||
|
Certara
CERT
|
105 M | $ 6.67 | 1.6 % | $ 1.07 B | ||
|
Athira Pharma
ATHA
|
-47.2 M | - | - | $ 269 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 3.6 | -4.0 % | $ 7.83 B | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M |